Checkpoint Therapeutics (CKPT) to Release Earnings on Friday

Checkpoint Therapeutics (NASDAQ:CKPT) is expected to be announcing its earnings results before the market opens on Friday, March 28th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ:CKPT opened at $4.06 on Thursday. Checkpoint Therapeutics has a one year low of $1.38 and a one year high of $4.50. The business’s 50-day simple moving average is $3.29 and its 200 day simple moving average is $3.23. The company has a market cap of $198.26 million, a P/E ratio of -2.21 and a beta of 1.41.

Wall Street Analyst Weigh In

CKPT has been the subject of several analyst reports. Lake Street Capital restated a “hold” rating and issued a $4.10 target price (down from $7.00) on shares of Checkpoint Therapeutics in a research note on Monday, March 10th. HC Wainwright reaffirmed a “neutral” rating and set a $4.10 target price on shares of Checkpoint Therapeutics in a research report on Tuesday, March 11th. Finally, D. Boral Capital reissued a “buy” rating and issued a $4.80 price target (down previously from $9.00) on shares of Checkpoint Therapeutics in a report on Monday, March 10th.

Insider Activity at Checkpoint Therapeutics

In other news, CFO William Garrett Gray sold 74,110 shares of Checkpoint Therapeutics stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $3.67, for a total value of $271,983.70. Following the completion of the transaction, the chief financial officer now directly owns 1,458,644 shares of the company’s stock, valued at approximately $5,353,223.48. The trade was a 4.84 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO James F. Oliviero III sold 9,233 shares of the firm’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $3.41, for a total transaction of $31,484.53. Following the completion of the transaction, the chief executive officer now directly owns 3,785,350 shares in the company, valued at $12,908,043.50. This represents a 0.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 93,674 shares of company stock valued at $336,011 over the last ninety days. Corporate insiders own 2.10% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.